Oculis announces First Patient First Visit in its Phase 2b RELIEF trial evaluating the potential of licaminlimab, Oculis’ innovative anti-TNFalpha biologic eye drop, for the treatment of Dry Eye Disease. 120 patients are planned to be randomized to either licaminlimab or vehicle for a 6-week treatment and a 2-week follow up period. Topline results are anticipated in mid-2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on OCS:
- Oculis Announces First Patient First Visit in Phase 2b RELIEF Trial of Topical Anti-TNFα Licaminlimab (OCS-02) in Dry Eye Disease
- Chardan starts Oculis with Buy on diabetic macular edema potential
- Oculis initiated with bullish view at Chardan
- Oculis price target lowered to $21 from $24 at BofA
- Oculis Reports Q3 2023 Financial Results and Provides Company Update